David H. Ilson, MD, PhD, on Improving Esophageal Cancer Outcomes: Future Directions
2018 Gastrointestinal Cancers SymposiumDavid H. Ilson, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the merits of preoperative chemotherapy vs chemoradiotherapy, the role of targeted agents, recent results from genomic profiling, and whether PET scans can guide neoadjuvant treatment.
Related Videos
Basem Azab, MD, on Esophageal Cancer: Study Survival Results
Basem Azab, MD, of the Sylvester Comprehensive Cancer Center, University of Miami, discusses the impact on overall survival when more than 2 months elapse between finishing neoadju...
Ramesh K. Ramanathan, MD, on Metastatic Pancreatic Cancer: Results From a SWOG Study
Ramesh K. Ramanathan, MD, of the Mayo Clinic, discusses early-phase study findings on mFOLFIRINOX (mFFOX) plus pegylated recombinant human hyaluronidase vs mFFOX alone in patients ...
Mark Saunders, MD, PhD, on Colorectal Cancer: Results From the SCOT Trial
Mark Saunders, MD, PhD, of Christie Hospital, discusses study findings on tumor sidedness and the influence of chemotherapy duration on disease-free survival (Abstract 558).<...
Ghassan K. Abou-Alfa, MD, on HCC: Results From the CELESTIAL Trial
Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III study findings on cabozantinib vs placebo in patients with advanced hepatocellular carcinom...
Pieter van der Sluis, MD, PhD, on Esophageal Cancer: Results From a Surgical Treatment Trial
Pieter van der Sluis, MD, PhD, of the University Medical Center Utrecht, discusses study findings that compared robot-assisted minimally invasive thoracolaparoscopic esophagectomy ...
